CSIMarket Company Name, Ticker, Industry, else..


Verastem Inc   (NASDAQ: VSTM)
Other Ticker:  
 


 

Verastem Inc

VSTM's Financial Statements and Analysis



Verastem Inc narrowed first quarter of 2025 net loss per share of $-0.96 compare to net loss per share of $-1.26 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.03 realized in previous quarter.


first quarter of 2025
Earnings Per Share Revenues
$ -0.96 $  0 Mill
$+0.30     Unch.    



Verastem Inc 's Revenue fell by 0 % in first quarter of 2025 (Mar 31 2025) year on year, to $0 million and declined by sequentially.


Verastem Inc is

More on VSTM's Income Statement



Verastem Inc in the first quarter of 2025 recorded net loss of $-52.103 million, an increase from net loss of $-33.863 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-64.551 million realized in previous quarter.

More on VSTM's Growth

Verastem Inc Inventories
VSTM's Cash flow In the first quarter of 2025 company's net cash flow was $29 million


Verastem Inc does not pay out common stock dividend.

In trailing twelve-month period Verastem Inc payed $ -2.13 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.60 per share from $ -0.81.

Company issued 18.48 million shares or 51.77 % in Mar 31 2025.


• More on VSTM's Dividends

 Market Capitalization (Millions) 412
 Shares Outstanding (Millions) 54
 Total Debt (Millions $) 72
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -149
 Cash Flow (TTM) (Millions $) 35
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 80




Verastem Inc does not pay out common stock dividend.

In trailing twelve-month period Verastem Inc had negative $ -2.13 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.60 per share from $ -0.81.

Company issued 18.48 million shares or 51.77 % in Mar 31 2025.


• More on VSTM's Balance Sheets

 Market Capitalization (Millions) 412
 Shares Outstanding (Millions) 54
 Total Debt (Millions $) 72
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -149
 Cash Flow (TTM) (Millions $) 35
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 80
   


  News about Verastem Inc Earnings

Verastem Inc Reports Contraction in Corporate Results for Fiscal Quarter Ending March 31, 2024

Verastem Inc, a pioneering biopharmaceutical company dedicated to developing innovative cancer treatments, has been making significant strides in the industry. The company recently announced its financial results for the first quarter of 2024, showcasing its commitment to advancing new medicines for patients with cancer.
One of the major highlights for Verastem Inc in the first quarter of 2024 was the FDA Orphan Drug Designation for the avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer. This designation is a crucial recognition of the unique nature of this rare cancer type and the potential benefits of the drug combination in treating it. The FDA Orphan Drug Designation...

Verastem Inc Faces Financial Struggles as Operating Loss Doubles in Fourth Quarter of 2023

The financial results of VSTM for the period ending December 31, 2023, have certainly raised some eyebrows within the Major Pharmaceutical Preparations industry. With an operating loss of $-31.139 million, it is clear that the company is facing some challenges in terms of generating profits.
Comparing these results to the previous year, where VSTM reported an operating loss of $-16.846 million, it is evident that the company's financial situation has deteriorated. This trend is further emphasized by the fact that the company's shortfalls have extended to $-27.368 million in the recent fiscal period.
Furthermore, the company announced a net loss of $-87.37 million and zero revenue in the financial pe...

Verastem Inc's Groundbreaking Triumph: Surges in Earnings for Q3 2023 Unveiled

Verastem Inc (VSTM) is a pharmaceutical company that has recently released its earnings report for the third quarter of 2023. The company reported an operating shortfall of $-21.309 million, which is a deterioration from the $-17.709 million shortfall reported in the same quarter of 2022. This news has left analysts wondering if Verastem Inc will be able to generate positive revenue in the near future.
Like many corporations, Verastem Inc has experienced ups and downs in its business strategy. The third quarter of 2023 seems to be one of these challenging periods, as the deficit has expanded to $-20.004 million. However, the company is actively working towards cultivating a lucrative business strategy, a...

Verastem Inc Sees Resilience in Challenging Market, Announces Operating Loss in Q2 2023



Verastem Inc, a prominent player in the Major Pharmaceutical Preparations industry, has recently reported a significant decrease in the past five trading days, lowering their share value by -12.01%. However, the year-to-date performance still stands at an impressive 2243.68%. Currently trading on the NASDAQ, Verastem Inc's shares are situated at a significant 359.3% above its 52-week average. Amidst these fluctuations, the company recently released its financial results for the second quarter of 2023, which presented both positive and challenging aspects.
Financial Performance Highlights:
Verastem Inc reported an operating loss of $-20.292 million for the second quarter of 2023, signaling a...

Verastem Inc's Latest Fiscal Period Highlights Lackluster Revenue and Continued Struggles

Verastem Inc: A Disappointing and Bearish Outlook
Verastem Inc seems to be struggling as it posts losses yet again, as seen in its recent fiscal period. The company reported a loss of $-0.08 per share, which is a decrease from $-0.09 a year prior. Although there is a slight improvement from the previous reporting season, the growing shortfall from $-0.07 per share is still a cause for concern.
The revenue of Verastem Inc remained unchanged at $0.00 million, which is a massive drop compared to the $2.60 million revenue from the same reporting season a year prior. This is a troubling sign for investors, and it indicates that the company is not heading in the right direction. Furthermore, the fact that ...


Date modified: 2025-05-15T07:37:19+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com